1. Background
2. Method
| Reference Number | Category | Focused on Vitamin/s | Dose | Route | Duration of Administration, d | Main Findings |
|---|---|---|---|---|---|---|
| (13) | Review | A, Bs, C, D, E | - | - | - | Efficient integrity of the mucosal epithelium |
| (14) | Review | A, D | - | - | - | Enhance the immune system |
| (15) | Review | A | - | - | - | Modulate immune system |
| (16) | Review | A | - | - | - | Modulator of the immune system via enhance immune cells proliferation |
| (17) | Animal study | A | 25 - 300, 1000 μg/mouse/day | Injection | 7 | T killer cell induction |
| (18) | In-vitro | A | - | - | - | Stimulates proliferation of T- Cells |
| (19) | Animal study | A | - | - | - | Stimulates proliferation of T-cells |
| (20) | Human study | A | 100.000 IU | Orally | - | Stimulation of immune system |
| (21) | Human study | A | 100.000 IU | Orally | - | Stimulation of immune system |
| (22) | Animal study | A | 400 IU, 0.1 mL | Injection | 7 | Reduce immune suppressive action of cortisone |
| (23) | Review | A | - | - | - | Modulator of the immune system |
| (24) | Animal study | B1 | - | - | - | Enhance lymphocytes activities |
| (25) | Review | B complex | - | - | - | Stimulation of the immune system functions |
| (26) | Animal study | B2 | 10 mg/kg bw/6 h, 80 mg/kg/6 h | Injection | - | Prevention and/or treatment of sepsis |
| (27) | In-vitro | B2, B9 | - | - | - | Stimulation of Mucosal-associated invariant cells |
| (28) | Review | B2 | - | - | - | Mucosal-associated invariant cells activation |
| (29) | Review | B3 | - | - | - | Boosts neutrophil counts |
| (30) | Review | B3 | - | - | - | Increases in neutrophil numbers |
| (31) | Review | B6 | - | - | - | Regulation of Immune Responses |
| (32) | Human study | B6 | 3, 15, 22.5, 33.75 μg /body weight/ day | - | 4 | Regulate IL-2 production and lymphocytes proliferation |
| (33) | Review | B6 | - | - | - | Thymic Epithelial Cells and T cells Differentiation |
| (34) | Animal study | B6 | 0.12 mg, and 120 mg/kg diets | Orally | 70 | Regulation of T- cells differentiation, IL-2 and IL-4 secretion |
| (35) | In-vitro and In Vivo | B9 | - | Orally | 90 | Regulation of T- cells |
| (36) | Review | B9 | - | - | - | Regulates gut immune system |
| (37) | Human study | B12 | 500 µg/day | Injection | 14 | Augmentation of CD8+ T cells and natural killer (NK) cell activity |
| (38) | Review | A, Bs, C, D, E | - | - | - | Support the protective activities of the immune cells |
| (39) | Virtual screening | B12 | - | - | - | Enhance the immune system |
| (40) | Review | C | - | - | - | Prevent and treat respiratory and systemic infections |
| (41) | Review | C | - | - | - | Shorten the duration of respiratory tract infections |
| (42) | Review | C | - | - | - | Enhance the immune system |
| (43) | Review | C | 50 mg/kg bw every 6 hours | Injection | 4 | Regulate inflammatory mediators |
| (44) | Review | D | - | - | - | Modulator of the immune system |
| (45) | Review | D | - | - | - | Modulation of innate and autoimmunity |
| (46) | Review | D | - | - | - | Enhance the immune system |
| (47) | Review | D | - | - | - | Barriers integrity, enhance chemo taxis, regulate inflammation |
| (48) | Review | D | - | - | - | Regulation of normal numbers of regulatory T-cells |
| (49) | Review | D | - | - | - | Modulate immune function and reduce the risk of infection |
| (50) | Review | D | - | - | - | Enhance the immune system |
| (51) | Review | E | - | - | - | Enhancing immunity in viral infections |
| (52) | Review | E | - | - | - | Stimulation of the immune system functions |
| (53) | Review | E | - | - | - | Enhance T- and B-cell-mediated functions |
| (54) | Review | E | - | - | - | Reduce the risk of infection and Modulate immune function |
| (55) | Human study | E | 400 mg | Orally | 30 | Enhances cell-mediated immunity |
| (56) | Review | E | - | - | - | Enhance the immune system |
| (57) | Review | E | - | - | - | Modulate immune function |
3. Results
| Vitamins Names | Reviewed References Numbers | Percentage of Studies Among Whole of Reviewed Studies | Percentage Studies About Association with COVID-19 | Mechanisms of Vitamins Effects on Immune System |
|---|---|---|---|---|
| Vitamin A | (13-23, 51) | 26.66% (12/45) | 16.66% (1/6) | Enhance cytotoxicity; T-cell proliferation; stimulation of IL-2 secretion and etc. |
| Group B vitamins | (24-39) | 42.18% (19/45) | 0% (0/6) | As below |
| Vitamin B1 | (24, 25) | 4.44% (2/45) | 0% (0/6) | Antioxidative effect; regulation of NF-κB; suppresses oxidative stress and etc. |
| Vitamin B2 | (25-28) | 8.88% (4/45) | 0% (0/6) | Reduce cytokines; reduce nitric oxide; T cells activation and etc. |
| Vitamin B3 | (25, 29, 30) | 6.66% (3/45) | 0% (0/6) | Reduce inflammation; reduction of TGF-β gene expression; regulation of plasma lipoproteins and etc. |
| Vitamin B6 | (31-34) | 8.88% (4/45) | 0% (0/6) | Proliferation and differentiation of lymphocytes; IL-2 synthesis; IL-4 regulation and etc. |
| Vitamin B9 | (25, 35, 36) | 6.66% (3/45) | 0% (0/6) | NF-κB regulation; Treg cells differentiation; Treg cells maintenance and etc. |
| Vitamin B12 | (37-39) | 6.66% (3/45) | 0% (0/6) | Regulation of cellular immunity; CD8+ cells regulation; Enhancement of natural killer cell system and etc. |
| Vitamin C | (40-43, 56) | 11.11% (5/45) | 50% (3/6) | Antioxidant activity; enzyme cofactor; regulation of B cells and T cells genes and etc. |
| Vitamin D | (14, 44-51, 56) | 22.22% (10/45) | 66.66% (4/6) | Cathelicidin up-regulation; activation of T cells; stimulation of antigen-presenting cells especially dendritic cells and etc. |
| Vitamin E | (52-57) | 13.33% (6/45) | 33.33% (2/6) | Ant oxidative effects; activation of T cells; suppression of prostaglandin E2 synthesis and etc. |
3.1. Vitamin A and Its Role on Immune System Stimulation
This figure is obtained from other study (14) and shows effects of vitamin A metabolites on gut mucosal immunity. A, In addition to upregulating the expression of gut-homing receptors, retinoic acid has also been reported to promote T-helper-2 (TH2)-cell differentiation. Moreover, retinoic acid blocks the differentiation of T helper 17 (TH17) cells and induces forkhead box protein 3 (FOXP3)+ regulatory T (TReg) cells in the presence of transforming growth factor-β (TGFβ) by reciprocally downregulating receptor-related orphan receptor-γt (RORγt) and inducing FOXP3 expression in T cells, respectively. Retinoic acid also enhances the TGFβ-driven induction of TReg cells and induces gut-homing receptor expression in both naturally occurring and induced TReg cells. TH17-cell differentiation requires TGFβ, interleukin-6 (IL-6), IL-23 and, in humans, IL-1β; B, B cells activated in non-mucosal lymphoid tissues, such as peripheral lymph nodes and spleen, mostly become IgG+ antibody-secreting cells (ASCs) and home to the bone marrow and sites of inflammation. By contrast, B cells activated in mucosal-associated lymphoid tissues (MALT) give rise to IgA+ ASCs. In MALT (including the gut-associated lymphoid tissue; GALT), TGFβ and CD40 ligand (CD40L) are essential for the generation of T-cell-dependent IgA responses, whereas BAFF (B-cell-activating factor) and APRIL (a proliferation-inducing ligand) are important for T-cell-independent IgA responses. APRIL is induced by Toll-like receptor (TLR) signals, commensal flora and thymic stromal lymphopoietin (TSLP). Inducible nitric oxide synthase (iNOS), which is also upregulated by TLR signals and commensal flora, produces nitric oxide (NO), allows proper TGFβ signalling and induces the production of APRIL and BAFF by dendritic cells. Thus, iNOS and NO are essential for both T-cell-dependent and -independent IgA responses. In the GALT, retinoic acid might contribute directly to the differentiation of T-cell-independent (and probably also T-cell-dependent) IgA+ ASCs. In addition, retinoic acid might contribute indirectly to T-cell-dependent and -independent IgA responses by inducing iNOS expression (14).
3.2. Vitamin B Group and Their Role on Immune System Stimulation
3.2.1. Vitamin B1 (Thiamin)
3.2.2. Vitamin B2 (Riboflavin)
3.2.3. Vitamin B3 (Niacin)
3.2.4. Vitamin B6 (Pyridoxine)
3.2.5. Vitamin B9 (Folic Acid)
This figure is obtained from other study (36) and shows vitamin‐mediated immune regulations in the gut. Vitamin A from diet is converted into retinoic acid (RA) by dendritic cells (DCs). B and T cells primed by DCs in the presence of RA express gut homing molecules (α4β7 integrin and CCR9). RA also promotes the differentiation of naïve T cells into regulatory T (Treg) cells. Upon the differentiation into the Treg cells, Treg cells start to express folate receptor 4 (FR4), a receptor for vitamin B9. The vitamin B9-FR4 axis is required for the survival of Treg cells. Vitamin D acts on Paneth cells on the epithelial layer and macrophages (MΦ) and aids production of antimicrobial peptides (AMPs). It also promotes the trafficking of intraepithelial lymphocyte (IEL) population and inhibits the maturation of DCs (36).
3.2.6. Vitamin B12 (Cobalamin)
3.3. Vit C (Ascorbic Acid) and Its Role on Immune System Stimulation
3.4. Vit D and Its Role on Immune System Stimulation
This picture is obtained from other study (14) and shows the mechanisms of vitamin D immunomodulation. Systemic or locally produced 1,25(OH)2VD3 exerts its effects on several immune-cell types, including macrophages, dendritic cells (DCs), T and B cells. Macrophages and DCs constitutively express vitamin D receptor (VDR), whereas VDR expression in T cells is only upregulated following activation. In macrophages and monocytes, 1,25(OH)2VD3 positively influences its own effects by increasing the expression of VDR and the cytochrome P450 protein CYP27B1. Certain Toll-like-receptor (TLR)-mediated signals can also increase the expression of VDR. 1,25(OH)2VD3 also induces monocyte proliferation and the expression of interleukin-1 (IL-1) and cathelicidin (an antimicrobial peptide) by macrophages, thereby contributing to innate immune responses to some bacteria. 1,25(OH)2VD3 decreases DC maturation, inhibiting upregulation of the expression of MHC class II, CD40, CD80 and CD86. In addition, it decreases IL-12 production by DCs while inducing the production of IL-10. In T cells, 1,25(OH)2VD3 decreases the production of IL-2, IL-17 and interferon-γ (IFNγ) and attenuates the cytotoxic activity and proliferation of CD4+ and CD8+ T cells. 1,25(OH)2VD3 might also promote the development of forkhead box protein 3 (FOXP3)+ regulatory T (TReg) cells and IL-10-producing T regulatory type 1 (TR1) cells. Finally, 1,25(OH)2VD3 blocks B-cell proliferation, plasma-cell differentiation and immunoglobulin production. ASCs, antibody-secreting cells (14).


